Impact of treatment effect on MRD and PFS: an aggregate data analysis from randomized clinical trials in multiple myeloma

Blood Adv. 2024 Jan 9;8(1):219-223. doi: 10.1182/bloodadvances.2023010821.

Authors

Bruno Paiva¹, Anastasiia Zherniakova¹, Jorge M Nuñez-Córdoba¹, Paula Rodriguez-Otero¹, Qian Shi², Nikhil C Munshi³, Brian G M Durie⁴, Jesus San-Miguel¹

Affiliations

¹ Cancer Center Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada, Instituto de Investigacion Sanitaria de Navarra, Cedars-Sinai Medical Center CB16/12/00369, Pamplona, Spain.
² Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN.
³ Dana-Farber Cancer Institute and Boston VA Healthcare System, Boston, MA.
⁴ Cedars-Sinai Medical Center, Los Angeles, CA.

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Disease-Free Survival
Humans
Multiple Myeloma* / drug therapy
Randomized Controlled Trials as Topic
Treatment Outcome